Basilea Pharmaceutica
Commercial stage biopharmaceutical company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $29.0m | Grant | |
| Total Funding | 000k | ||
| CHF | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 16 % | - | 7 % | 32 % | 4 % | 18 % | 11 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 2 % | 16 % | 15 % | 32 % | 25 % | 31 % | 34 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5 %) | 8 % | 7 % | 37 % | 23 % | 24 % | 25 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 63 % | 50 % | 49 % | 37 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Basilea Pharmaceutica is a biopharmaceutical company based in Basel, Switzerland, and listed on the SIX Swiss Exchange under the ticker SIX BSLN. The company specializes in the research, development, and commercialization of innovative anti-infective treatments. Its core products, Cresemba and Zevtera, are aimed at addressing severe bacterial and fungal infections. Basilea primarily serves healthcare providers, hospitals, and clinics worldwide, focusing on markets with high unmet medical needs in infectious diseases. The company operates on a business model that combines in-house research and development with strategic partnerships and licensing agreements to bring its products to market. Revenue is generated through product sales, royalties, and milestone payments from partners.
Keywords: biopharmaceutical, anti-infective, Cresemba, Zevtera, healthcare, hospitals, clinics, research, development, commercialization.